Is Genesystem (KOSDAQ:363250) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. We can see that Genesystem Co., Ltd. (KOSDAQ:363250) does use debt in its business. But the real question is whether this debt is making the company risky.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

When Is Debt A Problem?

Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. If things get really bad, the lenders can take control of the business. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

What Is Genesystem's Net Debt?

The image below, which you can click on for greater detail, shows that Genesystem had debt of ₩3.76b at the end of June 2025, a reduction from ₩4.30b over a year. But on the other hand it also has ₩4.02b in cash, leading to a ₩262.1m net cash position.

How Healthy Is Genesystem's Balance Sheet?

Zooming in on the latest balance sheet data, we can see that Genesystem had liabilities of ₩2.38b due within 12 months and liabilities of ₩5.35b due beyond that. On the other hand, it had cash of ₩4.02b and ₩108.2m worth of receivables due within a year. So it has liabilities totalling ₩3.60b more than its cash and near-term receivables, combined.

Given Genesystem has a market capitalization of ₩34.7b, it's hard to believe these liabilities pose much threat. However, we do think it is worth keeping an eye on its balance sheet strength, as it may change over time. While it does have liabilities worth noting, Genesystem also has more cash than debt, so we're pretty confident it can manage its debt safely. When analysing debt levels, the balance sheet is the obvious place to start. But it is Genesystem's earnings that will influence how the balance sheet holds up in the future. So when considering debt, it's definitely worth looking at the earnings trend. Click here for an interactive snapshot.

View our latest analysis for Genesystem

In the last year Genesystem wasn't profitable at an EBIT level, but managed to grow its revenue by 92%, to ₩1.1b. With any luck the company will be able to grow its way to profitability.

So How Risky Is Genesystem?

By their very nature companies that are losing money are more risky than those with a long history of profitability. And we do note that Genesystem had an earnings before interest and tax (EBIT) loss, over the last year. And over the same period it saw negative free cash outflow of ₩8.1b and booked a ₩8.8b accounting loss. Given it only has net cash of ₩262.1m, the company may need to raise more capital if it doesn't reach break-even soon. Genesystem's revenue growth shone bright over the last year, so it may well be in a position to turn a profit in due course. By investing before those profits, shareholders take on more risk in the hope of bigger rewards. When analysing debt levels, the balance sheet is the obvious place to start. However, not all investment risk resides within the balance sheet - far from it. For example, we've discovered 4 warning signs for Genesystem (2 are concerning!) that you should be aware of before investing here.

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.